||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Valirx Share Discussion Threads
Showing 18551 to 18572 of 18575 messages
|Few takers even at these prices..???
Today 10:04 Price: 3.75
MrBB 1,022 posts
If Johnson & Johnson, or BTG considered 201 to be a thread to their position, (with revenue to JJ of about $1 bill & royalties to BTG in excess of $30mill ) , surely they would eith acquire 201 or the whole of Val, for a relatively modest amount in order to either shelve it or develope it to work in conjunction . Their apparent lack of interest suggests that that they do not see 201 as any type of threat to their position.
Off Topic No Opinion|
|Could it be a forthcoming CLN conversion? YA or Bracknor perhaps?|
|looks a bit cheap for someone who is making drugs for something like prostate cancer.
Are the board lying?|
|neo..you tell me after you have read all the relevant stuff,I'm as just in the dark has everyone else associated with this but our share price tells another story..|
|"....ValiRx is entering a very exciting phase, which should result in the crystallisation of substantial value".This was in Jan so what has changed?|
|Bossman which RNs, last RNs was 11 Jan...|
|neo..read the RNS and you will know its that simple,also drop GM an email he might have an answer for you too..But don't hold your breath..|
|What happened to this company?Do they need more cash?Its on ridiculous levels.|
|Will creep back up again next week.|
|Bobby..if that's the case then why are we still trading then ..???|
|What a week.|
|I think you should also look at the emperors clothes errrr I mean 201 and 401
remember this is AIM ! ! ! ! !
23 Feb '17 - 22:51 - 5088 of 5095
301?the missing compound?
24 Feb '17 - 08:19 - 5089 of 5095
Max..it did not go missing, maybe it was never there in the first place.|
|Two times 150,000 sells again at end of day same as yesterday|
|as you say,bossman,either there is something/someone that is interested in getting it as low as possible(probably to launch a bid)or all these good reports don`t make up....this is valued 99% LESS than when it started!|
|Annual Report and Accounts 2015 ValiRx plc..For all to see and from the horses mouth...So why the decline in our share price ..??
Lung Cancer and others
VAL401 is the reformulation of a generic drug
that has over 20 years of clinical use for treatment
of a chronic non-oncology disease in an oral
capsule. The re-formulation allows the drug to
access previously unexploited anti-cancer activity.
VAL401 is progressing satisfactorily through its
remaining preclinical development and towards
clinical Phase II trials for the treatment of lung
cancer and other oncology indications. Progress
into clinical trials will comprise a shorter than
usual route to Market Authorisation by use
of prior clinical data gathered on the original
generic drug. Preclinical efficacy data has been
collected in both non-small cell lung and prostate
cancers. Preclinical toxicology has revealed no
side effects beyond those expected from the
parent drug, with preclinical pharmacokinetc
data allowing bridging from VAL401 to the
historical full clinical data package on the parent.
Formulation stability tests are currently underway
to complete the CMC package.......
During 20 years of prior clinical use, the active
drug has been safely administered long term
(chronic use of over 2 year’s duration) with
Other possible indications include....
prostate and pancreatic cancer.
“I am delighted that VAL401
has progressed according
to schedule since being
in-licensed to the ValiRx
group last year. We look
forward to hearing reports
from ValiSeek of further
advancement over the
Dr Satu Vainikka
Chief Executive Officer
In conclusion, the period under review has been
pleasingly satisfactory and our teams around
the VAL201 and VAL401 compounds have started
talking to parties for late stage clinical studies
and for potential partnerships and collaboration
with pharmaceutical partners.
ValiRx continues to look to expand its Intellectual
Property (“IP”) as its development programmes
go forward and it remains open to technology
acquisition opportunities and ways in which it
can both deliver and grow shareholder value.
|ValiRx PLC, VAL:LSE financials - FT.com
Traducir esta página
ValiRx PLC (VAL:LSE) financials, including income statements, growth rates, balance sheets and cash ... ValiRx PLC uses little or no debt in its capital structure.
Iv taken everything into account and logic dictates something is very fishy when we have had no bad news with the trials etc etc,when we consolidated we started a [email protected] more important we have no debt i believe as such.....quote“When you eliminate the impossible, whatever remains, however improbable, must be the truth.”|
|You haven't taken into account the highly dillutive wonga style funding spiral of death. I've written this share off, live and learn. Until bracknor are out and warrants disposed of this is going to continue to be strangled to death. The Bod have probably woken up to the fact that they screwed up big time with the wonga funding and have stuck their heads in the sand over it.|
|it also makes no sense the share price would be dragged this low if has our BOD are saying we have news soon that will move the share price to where it was at 50p+...This would make the MMs look very foolish unless they know different..Aimo|
|Max..it did not go missing, maybe it was never there in the first place.|
|301?the missing compound?|
|More stronger words are needed from you JG especially with the amount of dosh you say you have invested in valirx..
Today 19:43 Price: 4.00
johngilchrist 6,932 posts
RE: Top Up
No i'm not exactly thrilled with their performance. They have failed to deliver a commercial deal, and the salesman seemed to get sacked for that. I don't think that they had that much control of the really weak funding environment on AIM, and the lack of interest from institutional investors. A key failure seems in PR and marketing, and the lack of attracting any independent valuation via broker notes. Currently the company is being valued based on the past performance of a 2 year chart, and that isn't very appealing. Looking forward there should be plenty of trial news ahead on 201, 401 and 301. But concerns on forward funding continue to haunt us.|